Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22951279 | 0.81 | FAAH (0.40) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL1864917 | 0.81 | FAAH (0.40) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL22501848 | 0.81 | ELANE (0.44) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL22233152 | 0.79 | FAAH (0.39) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL28739878 | 0.79 | ELANE (0.42) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL21640187 | 0.78 | ALDH1A1 (0.36) | ELANEALDH1A1MAPK1 | |
| SCHEMBL30879097 | 0.78 | FAAH (0.41) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL362915 | 0.78 | FAAH (0.38) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL16630273 | 0.78 | GABRA1 (0.40) | FAAHELANEBCHEMAPK1POLB | |
| SCHEMBL16059069 | 0.77 | FAAH (0.40) | FAAHELANEBCHEMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916747-A | Fused heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115209952-A | Substituted pyrazolopyrimidines and use thereof | 维基分析有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-111212833-B | Phenylpyridine derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2022-09-06 | — | — | CN | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-108026077-B | Phenoxymethyl derivatives | 豪夫迈·罗氏有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3344619-B1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-10640472-B2 | Phenoxymethyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3344619-A1 | PHENOXYMETHYL DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| CN-101405001-A | Methods of inhibiting BTK and SYK protein kinases | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | FAAH 3794/4885ELANE 2985/4885ALDH1A1 131/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | FAAH 4108/4885ELANE 2970/4885ALDH1A1 4695/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | FAAH 4108/4885ELANE 2970/4885ALDH1A1 4695/4885 |
| US-10640472-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | FAAH 3794/4885ELANE 2985/4885ALDH1A1 131/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | FAAH 4108/4885ELANE 2970/4885ALDH1A1 4695/4885 |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | FAAH 3794/4885ELANE 2985/4885ALDH1A1 131/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | FAAH 3794/4885ELANE 2985/4885ALDH1A1 131/4885 |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | FAAH 3150/4885ELANE 1326/4885ALDH1A1 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.